Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:14 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Testing a Personally Controlled Health Record to Ameliorate Influenza at MIT

NCT00531700
View directory record Official record
Conditions
Influenza
Interventions
Health messaging, Health messages
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2009 · Synced Nov 2, 2026, 9:14 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RCT of QPS vs General Information Sheet

NCT03287492
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Caregiver, Physician
Interventions
Informational Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Nov 2, 2026, 9:14 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

NCT04901715
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
Drug · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 4 Interventional Results available

The END Perioperative Smoking Pilot Study

NCT02482233
View directory record Official record
Conditions
Smoking, Nicotine Addiction, Surgery
Interventions
ENDD (NJOY), NRT (NicoDerm CQ), telephone counseling, brief advice, brochure
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Nov 2, 2026, 9:14 AM EST
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Phase 2 Interventional Results available

Placebo Controlled Trial of Bosentan in Scleroderma Patients

NCT00377455
View directory record Official record
Conditions
Systemic Scleroderma, Pulmonary Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Not applicable Interventional Results available

Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients

NCT02173522
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate artery embolization (PAE)
Device
Lead sponsor
Shivank Bhatia
Other
Eligibility
45 Years to 79 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

NCT04566601
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Anaheim, California • Temecula, California • Upland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Phase 2 Interventional Results available

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

NCT00910039
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, cognitive assessment
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

NCT00001057
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
7
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Dose Finding Study of HP802-247 in Venous Leg Ulcers

NCT00852995
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Stasis Ulcers
Interventions
HP802-247, Placebo (Vehicle)
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
29
States / cities
Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 4 Interventional

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

NCT00060931
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
119
States / cities
Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Nov 2, 2026, 9:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiology and Treatment of Reading Disability in NF-1

NCT00624234
View directory record Official record
Conditions
Neurofibromatosis Type 1, Reading Disabilities
Interventions
Tutoring Program I, Tutoring Program II
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 17 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

NCT03677141
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

NCT04171765
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Placebo, BFKB8488A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
39
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

NCT00133536
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 9 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 2, 2026, 9:14 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

NCT00631878
View directory record Official record
Conditions
Neonatal Staphylococcal Sepsis
Interventions
Pagibaximab (formerly BSYX-A110)
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
3 Days to 7 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Nov 2, 2026, 9:14 AM EST